# Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer

> **NCT04836728** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 156 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic
- First-line Treatment

## Interventions

- **BIOLOGICAL:** CIK cells injection
- **DRUG:** Sintilimab Injection
- **DRUG:** Pemetrexed
- **DRUG:** Albumin paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04836728
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-31
- **Primary completion:** 2024-04-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04836728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04836728, "Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04836728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*